Metabolic Bone Disease AND Vitamin D Disorders — Written Clinical Reasoning · Phys Written Answers

Prompt

DCE-style written reasoning for Metabolic Bone Disease AND Vitamin D Disorders.

SAQ 1 — Integrated plan (12 marks)

Prompt: Provide a prioritised problem list and management sequence for this presentation. [1] [2]

Model Answer

1. Frame and red flags (3 marks) [1]

State the working diagnosis/syndrome, acuity, and what would force emergency treatment now. [1] [2]

2. Discriminating assessment (3 marks) [2]

List the key history, examination and investigations that separate dangerous differentials from benign mimics. [1] [2]

3. Treatment sequence (4 marks) [1] [3]

Immediate stabilisation, disease-specific therapy, monitoring, and complications prevention. [1] [2] [3]

4. Follow-up and communication (2 marks) [2]

Disposition, safety-net advice, and who owns follow-up. [1] [2]

SAQ 2 — Exam trap defence (8 marks)

Prompt: Name two high-yield traps in Metabolic Bone Disease AND Vitamin D Disorders and how you avoid them. [1] [2]

Model Answer

Trap one: delayed escalation of a high-risk feature — avoid by explicit red-flag checklist. [1]

Trap two: therapy mismatched to mechanism — avoid by confirming the discriminating test before escalating treatment. [2] [3]

References

[1]Amouroux C, Porquet-Bordes V, Adler E, Goff YL, et al. French national diagnosis and care protocol (PNDS) for infantile idiopathic hypercalcemia (IIH) Orphanet J Rare Dis, 2026.PMID 42469912
[2]Zhuang J, Su D, Gao Q, Hu L, et al. Evaluating combined acupuncture and antiresorptive therapy in Chinese women with postmenopausal osteoporosis: a systematic review and network meta-analysis Front Endocrinol (Lausanne), 2026.PMID 42460309
[3]Yang R, Zeng H, Xiao Q, Xie Y, et al. Endocrine‑metabolic imbalance drives osteoarthritis: From whole‑joint pathobiology to precision therapy (Review) Int J Mol Med, 2026.PMID 42429052
[4]Premikha M, Ricci V, Kan SJ, Expert Group of the Osteoporosis ACG, et al. Translating evidence into primary care: Singapore's 2025 national osteoporosis guideline and a multilevel framework for assessing guideline impact in mixed health systems Fam Med Community Health, 2026.PMID 42399071
[5]Sidbury R, Alikhan A, Bercovitch L, Cohen DE, et al. Guidelines of care for the primary prevention of atopic dermatitis and awareness of comorbid conditions in pediatric atopic dermatitis J Am Acad Dermatol, 2026.PMID 41949509
[6]Sosa-Henríquez M, Torregrosa-Suau Ó, Gómez de Tejada-Romero MJ, Cancelo-Hidalgo MJ, et al. Rethinking Vitamin D Deficiency: Controversies and Practical Guidance for Clinical Management Nutrients, 2025.PMID 41305623
[7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
[8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922

SAQ 1 — Integrated plan (12 marks)

Prompt: Provide a prioritised problem list and management sequence for this presentation. [1] [2]

Model Answer

1. Frame and red flags (3 marks) [1]

State the working diagnosis/syndrome, acuity, and what would force emergency treatment now. [1] [2]

2. Discriminating assessment (3 marks) [2]

List the key history, examination and investigations that separate dangerous differentials from benign mimics. [1] [2]

3. Treatment sequence (4 marks) [1] [3]

Immediate stabilisation, disease-specific therapy, monitoring, and complications prevention. [1] [2] [3]

4. Follow-up and communication (2 marks) [2]

Disposition, safety-net advice, and who owns follow-up. [1] [2]

SAQ 2 — Exam trap defence (8 marks)

Prompt: Name two high-yield traps in Metabolic Bone Disease AND Vitamin D Disorders and how you avoid them. [1] [2]

Model Answer

Trap one: delayed escalation of a high-risk feature — avoid by explicit red-flag checklist. [1]

Trap two: therapy mismatched to mechanism — avoid by confirming the discriminating test before escalating treatment. [2] [3]

References

[1]Amouroux C, Porquet-Bordes V, Adler E, Goff YL, et al. French national diagnosis and care protocol (PNDS) for infantile idiopathic hypercalcemia (IIH) Orphanet J Rare Dis, 2026.PMID 42469912
[2]Zhuang J, Su D, Gao Q, Hu L, et al. Evaluating combined acupuncture and antiresorptive therapy in Chinese women with postmenopausal osteoporosis: a systematic review and network meta-analysis Front Endocrinol (Lausanne), 2026.PMID 42460309
[3]Yang R, Zeng H, Xiao Q, Xie Y, et al. Endocrine‑metabolic imbalance drives osteoarthritis: From whole‑joint pathobiology to precision therapy (Review) Int J Mol Med, 2026.PMID 42429052
[4]Premikha M, Ricci V, Kan SJ, Expert Group of the Osteoporosis ACG, et al. Translating evidence into primary care: Singapore's 2025 national osteoporosis guideline and a multilevel framework for assessing guideline impact in mixed health systems Fam Med Community Health, 2026.PMID 42399071
[5]Sidbury R, Alikhan A, Bercovitch L, Cohen DE, et al. Guidelines of care for the primary prevention of atopic dermatitis and awareness of comorbid conditions in pediatric atopic dermatitis J Am Acad Dermatol, 2026.PMID 41949509
[6]Sosa-Henríquez M, Torregrosa-Suau Ó, Gómez de Tejada-Romero MJ, Cancelo-Hidalgo MJ, et al. Rethinking Vitamin D Deficiency: Controversies and Practical Guidance for Clinical Management Nutrients, 2025.PMID 41305623
[7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
[8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922